Bantam has raised approximately $25 million from private investors. The company and its current investors are seeking to syndicate a Series B round to:

1) Initiate Phase 1 first in human studies and generate a clinical proof of concept
2) Conduct translational studies to identify and prioritize additional tumor types for clinical development
3) Establish our unique Mechanism of Action as the foundation for a novel drug discovery platform to advance our existing pipeline and discover novel compounds

The above activities offer multiple near-term catalysts, including bringing the company to an exit via partnering event (licensing or acquisition by a Pharma/Biotech company) with a significant investor ROI.